AdAlta Inks Strategic Deal with Cell Therapies to Advance Cellular Immunotherapies

AdAlta Ltd. signs a strategic agreement with Cell Therapies Pty Ltd, designating CTPL as the preferred manufacturing partner for AdAlta's cellular immunotherapies. The partnership aims to enhance AdAlta's AdCella venture, providing support in product development, manufacturing, and supply chain operations.

author-image
Aqsa Younas Rana
New Update
AdAlta Inks Strategic Deal with Cell Therapies to Advance Cellular Immunotherapies

AdAlta Inks Strategic Deal with Cell Therapies to Advance Cellular Immunotherapies

Australian biotech company AdAlta Ltd. (ASX: 1AD) has signed a strategic agreement with Cell Therapies Pty Ltd (CTPL), designating CTPL as the preferred manufacturing partner for AdAlta's cellular immunotherapies. The collaboration aims to enhance AdAlta's AdCella venture by providing crucial support in product development, manufacturing, and supply chain operations.

Why this matters: This partners, advances has the potential to bring innovative cancer therapies to patients globally, addressing a significant unmet medical need. The collaboration could also pave the way for further advancements in cellular immunotherapies, leading to improved treatment options and better patient outcomes.

Under the terms of the Master Services Agreement (MSA), CTPL will offer a range of services to AdCella, including process development, technology transfer, analytical testing, clinical product manufacturing and supply, as well as regulatory support. The agreement establishes service standards, governance mechanisms, and customary terms related to starting and ending projects.

AdCella, a jointly owned entity with venture capital firm SYNthesis BioVentures (SYNBV), aims to facilitate the entry of innovative cellular immunotherapies from Asia into western regulated markets, leveraging AdAlta's i-body technology. The partnership with CTPL provides AdCella with access to deep experience in development and manufacturing of cellular immunotherapies and state-of-the-art facilities.

Dr. Tim Oldham, CEO and Managing Director of AdAlta, emphasized the significance of the collaboration, stating, "The collaboration with CTPL is the next key building block in our strategy to bring highly innovative cellular immunotherapies into a western regulated environment." Dr. Bev Menner, CEO of CTPL, expressed confidence in the partnership, noting, "We are impressed by the vision and expertise of AdAlta and SYNBV, and we are confident that our experience and networks enable us to provide them with high-quality product development, manufacturing, and clinical supply services that meet the expectations of regulators around the world."

CTPL, Australia's leading contract manufacturer of cellular immunotherapies for clinical trials and commercial supply, has been developing and manufacturing cutting-edge treatments for cancer and rare diseases on behalf of local and international clients for more than 20 years. The company's facilities are co-located with the Peter MacCallum Cancer Centre in Melbourne's Parkville Precinct and are Australia's only biomedical manufacturing facility where CAR T cells and other living cancer therapies can be made at commercial volumes.

Initial work under the MSA is anticipated to include technical feasibility assessments of AdAlta's in-licensing candidates. Financial costs and timelines of each project will be set out in individual work orders to be agreed as required and are not anticipated to be material prior to AdCella securing rights to its first assets.

The strategic partnership between AdAlta and Cell Therapies marks a significant step towards delivering innovative cancer therapies to patients. By leveraging Cell Therapies' expertise and state-of-the-art facilities, AdAlta can accelerate the development and manufacturing of its cellular immunotherapies, bringing groundbreaking treatments from Asia to global markets.

Key Takeaways

  • AdAlta partners with Cell Therapies as preferred manufacturing partner for cellular immunotherapies.
  • Collaboration aims to bring innovative cancer therapies to patients globally.
  • Cell Therapies to provide process development, manufacturing, and regulatory support to AdAlta.
  • Partnership enables AdAlta to accelerate development and manufacturing of cellular immunotherapies.
  • AdAlta's AdCella venture to leverage Cell Therapies' expertise and facilities to bring Asian therapies to western markets.